RxDoctor Payments DataLook up a doctor →

Shawn Kwatra, MD

Dermatology · Baltimore, MDNPI 1205191400

Payments from drug & device makers

$2,364,968in general payments, 2019–2025

Across 749 payments — averaging $3157.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$836K
  • Sanofi$454K
  • Regeneron$363K
  • Incyte Corporation$260K
  • Sanofi US Services Inc.$123K
  • Galderma Laboratories, L.p.$106K
  • plus $221K from 19 others
$66,858in research payments, 2019–2025

Across 83 payments — averaging $805.52 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$35K
  • Sanofi$18K
  • Novartis$8K
  • Regeneron$3K
  • AbbVie$3K
  • Sanofi-aventis U.S. LLC$750

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,364,968 in reported general payments places this provider in the 95th percentile of 306 dermatology providers in Maryland.

See all dermatology providers in Maryland

Medicare billing

Part B allowed, 2024
$63,019
Medicare patients
254
Services billed
714

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other dermatology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →